---

Natural Capsules Ltd (NCL): A Snapshot for Global Investors.

~Sumon Mukhopadhyay 

-----------

Introduction:

Natural Capsules Ltd (Rs.227), founded in 1993 and headquartered in Bengaluru, is a leading Indian manufacturer of empty hard gelatin and HPMC (vegetarian) capsules for the pharmaceutical, nutraceutical, and herbal industries. Photo: Natural Capsules Ltd (LinkedIn).

With WHO-GMP certification and an installed capacity of over 19.5 billion capsules annually, NCL has built a resilient core business. In recent years, the company has expanded into Active Pharmaceutical Ingredient (API) manufacturing through its subsidiary, Natural Biogenex. 

This overview examines NCL’s financial performance, global trade positioning, and policy tailwinds, offering insights for long-term investors.

Financial Performance: Growth with Caveats:

In Q1FY26, NCL reported a 13.04% year-over-year (YoY) rise in standalone net sales to ₹44.24 crore, reflecting strong domestic demand and recovering exports. Net profit margin stood at 11.7%, with EPS at ₹2.11. 

Despite this steady growth, ICRA downgraded NCL in August 2025 to BB+/A4+, citing weak performance from its API subsidiary and low interest coverage. For FY26, EPS is projected in the ₹3.00–₹3.50 range, provided the API unit scales up effectively and raw material costs remain manageable.

Navigating Global Trade Pressures:

A crucial support for NCL’s export business—nearly 20% of its revenue—is the ongoing US tariff exemption for Indian pharmaceuticals. While this shields capsule exports in the near term, the exemption is under review, with modest duties possible soon and steeper levies by mid-2026. This uncertainty reinforces the importance of NCL’s diversification strategy and its focus on strengthening domestic market share.

Policy Tailwinds in India:

India’s policy push for pharmaceutical self-reliance provides meaningful upside for NCL. Programs such as the Production-Linked Incentive (PLI) scheme and the Promotion of Research & Innovation (PRIP) initiative are designed to strengthen high-value API manufacturing. 

These measures, aligned with the “Atmanirbhar Bharat” (Self-Reliant India) vision, target 7–9% sectoral growth in FY26 and $130 billion in exports by 2030. NCL, with its dual focus on capsules and APIs, is well-positioned to benefit from these incentives.

Conclusion:

Natural Capsules Ltd presents a balanced investment case. Its established capsule segment offers stability, supported by domestic demand and short-term tariff relief. Yet, future growth depends on overcoming two hurdles: improving the performance of its debt-laden API subsidiary and sustaining profitability amid raw material volatility. With government incentives providing strong sectoral support, NCL remains a promising but cautious play on India’s pharmaceutical growth story.